Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Relapsed and Previously Untreated CLL Patients

NCT04624633 is registered in ClinicalTrials.gov with Jennifer R. Brown, MD, PhD as lead sponsor.

NCT NCT04624633
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04624633 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Relapsed and Previously Untreated CLL Patients
Lead sponsor
Jennifer R. Brown, MD, PhD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
December 15, 2020
Completion date
January 1, 2028
Enrollment
29 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia, refractory chronic lymphocytic leukemia, relapsed chronic lymphocytic leukemia, small lymphocytic lymphoma